Cargando…
Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
Assessment of treatment response to targeted therapies such as everolimus is difficult, especially in slow-growing tumors such as NETs. In this retrospective study, 17 patients with pancreatic neuroendocrine tumors (pNETs) and hepatic metastases (NELMs) (42 target lesions) who received everolimus we...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599819/ https://www.ncbi.nlm.nih.gov/pubmed/36289880 http://dx.doi.org/10.3390/biomedicines10102618 |
_version_ | 1784816686785888256 |
---|---|
author | Ingenerf, Maria Kiesl, Sophia Winkelmann, Michael Auernhammer, Christoph J. Rübenthaler, Johannes Grawe, Freba Fabritius, Matthias P. Ricke, Jens Schmid-Tannwald, Christine |
author_facet | Ingenerf, Maria Kiesl, Sophia Winkelmann, Michael Auernhammer, Christoph J. Rübenthaler, Johannes Grawe, Freba Fabritius, Matthias P. Ricke, Jens Schmid-Tannwald, Christine |
author_sort | Ingenerf, Maria |
collection | PubMed |
description | Assessment of treatment response to targeted therapies such as everolimus is difficult, especially in slow-growing tumors such as NETs. In this retrospective study, 17 patients with pancreatic neuroendocrine tumors (pNETs) and hepatic metastases (NELMs) (42 target lesions) who received everolimus were analyzed. Intralesional signal intensities (SI) of non-contrast T1w, T2w and DCE imaging, and apparent diffusion coefficients (ADCmean and ADCmin) of DWI, were measured on baseline and first follow-up MRI after everolimus initiation. Response assessment was categorized according to progression-free survival (PFS), with responders (R) showing a PFS of ≥11 months. ADCmin of NELMs decreased in Rs whereas it increased in non-responders (NR). Percentual changes of ADCmin and ADCmean differed significantly between response groups (p < 0.03). By contrast, ADC of the pNETs tended to increase in Rs, while there was no change in NRs. Tumor-to-liver (T/L) ratio of T1 SI of NELMs increased in Rs and decreased in NRs, and percentual changes differed significantly between response groups (p < 0.02). T1 SI of the pNETs tended to decrease in Rs and increase in Ns. The quotient of pretherapeutic and posttherapeutic ADCmin values (DADCmin) and length of everolimus treatment showed significant association with PFS in univariable Cox analysis. In conclusion, quantitative MRI, especially DWI, seems to allow treatment assessment of pNETs with NELMs under everolimus. Interestingly, the responding NELMs showed decreasing ADC values, and there might be an opposite effect on ADC and T1 SI between NELMs and pNETs. |
format | Online Article Text |
id | pubmed-9599819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95998192022-10-27 Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters Ingenerf, Maria Kiesl, Sophia Winkelmann, Michael Auernhammer, Christoph J. Rübenthaler, Johannes Grawe, Freba Fabritius, Matthias P. Ricke, Jens Schmid-Tannwald, Christine Biomedicines Article Assessment of treatment response to targeted therapies such as everolimus is difficult, especially in slow-growing tumors such as NETs. In this retrospective study, 17 patients with pancreatic neuroendocrine tumors (pNETs) and hepatic metastases (NELMs) (42 target lesions) who received everolimus were analyzed. Intralesional signal intensities (SI) of non-contrast T1w, T2w and DCE imaging, and apparent diffusion coefficients (ADCmean and ADCmin) of DWI, were measured on baseline and first follow-up MRI after everolimus initiation. Response assessment was categorized according to progression-free survival (PFS), with responders (R) showing a PFS of ≥11 months. ADCmin of NELMs decreased in Rs whereas it increased in non-responders (NR). Percentual changes of ADCmin and ADCmean differed significantly between response groups (p < 0.03). By contrast, ADC of the pNETs tended to increase in Rs, while there was no change in NRs. Tumor-to-liver (T/L) ratio of T1 SI of NELMs increased in Rs and decreased in NRs, and percentual changes differed significantly between response groups (p < 0.02). T1 SI of the pNETs tended to decrease in Rs and increase in Ns. The quotient of pretherapeutic and posttherapeutic ADCmin values (DADCmin) and length of everolimus treatment showed significant association with PFS in univariable Cox analysis. In conclusion, quantitative MRI, especially DWI, seems to allow treatment assessment of pNETs with NELMs under everolimus. Interestingly, the responding NELMs showed decreasing ADC values, and there might be an opposite effect on ADC and T1 SI between NELMs and pNETs. MDPI 2022-10-18 /pmc/articles/PMC9599819/ /pubmed/36289880 http://dx.doi.org/10.3390/biomedicines10102618 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ingenerf, Maria Kiesl, Sophia Winkelmann, Michael Auernhammer, Christoph J. Rübenthaler, Johannes Grawe, Freba Fabritius, Matthias P. Ricke, Jens Schmid-Tannwald, Christine Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters |
title | Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters |
title_full | Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters |
title_fullStr | Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters |
title_full_unstemmed | Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters |
title_short | Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters |
title_sort | treatment assessment of pnet and nelm after everolimus by quantitative mri parameters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599819/ https://www.ncbi.nlm.nih.gov/pubmed/36289880 http://dx.doi.org/10.3390/biomedicines10102618 |
work_keys_str_mv | AT ingenerfmaria treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT kieslsophia treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT winkelmannmichael treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT auernhammerchristophj treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT rubenthalerjohannes treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT grawefreba treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT fabritiusmatthiasp treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT rickejens treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters AT schmidtannwaldchristine treatmentassessmentofpnetandnelmaftereverolimusbyquantitativemriparameters |